This episode covers the FDA’s five ten k clearance of Cara Medical’s AI-based cardiac conduction system visualization platform for structural heart procedures, the agency’s formalization of single-trial pathways for new drug applications after decades of informal two-trial expectations, unresolved endpoint selection challenges in brain-computer interface pivotal trial design despite breakthrough device designations, and AACR oncology research documenting targeted therapeutics and real-world evidence frameworks for accelerated approval verification. The briefing examines how regulatory pathway formalization in pharmaceutical development contrasts with ongoing measurement ambiguity in novel device categories, while real-world evidence informs both post-approval verification and internal agency AI deployment.
